NASDAQ$ZYXIQ

Zynex Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Zynex's revenue increased, driven by a growth in device orders and customer base, while the company continued to invest in its pipeline and stock buyback program.

Zynex reported a 22% increase in revenue to $45.0 million for Q2 2023, with EPS at $0.09. The company saw a 51% growth in device orders and continued its stock buyback program.

  • Revenue increased by 22% year-over-year to $45.0 million.
  • Earnings per share (EPS) reached $0.09.
  • Gross profit increased to $35.7 million, representing 79% of revenue.
  • Device orders increased by 51% year-over-year.

Headline financials

Total Revenue

$45M

Previous: $36.8M+22.3%
EPS (adj)

$0.09

Previous: $0.08+12.5%
Capital Expenditures

-$394K

Previous: -$212K-85.8%
Free Cash Flow

$2.28M

Previous: $1.37M+67.0%
Net Income

$3.35M

Previous: $3.35M+0.2%
Operating Income

$2.71M

Previous: $4.36M-37.8%
Gross Profit

$35.7M

Previous: $29.5M+21.1%
Cash & Equivalents

$58.7M

Previous: $26.9M+118.6%
Total Assets

$153M

Previous: $120M+27.6%
Stock-Based Comp

$660K

Previous: $535K+23.4%

Revenue & EPS history

Zynex · Revenue · Quarterly

$45M

Q2 2023+22.3%vs Q2 2022
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Zynex · $49.9M total across 2 segments · Q3 2023

  • Supplies
    $33.1M
  • Devices
    $16.9M

Forward guidance

Zynex anticipates revenue between $49 million and $51 million for Q3 2023, representing approximately 20% growth year-over-year. Diluted EPS is expected to be between $0.08 and $0.10. Full year 2023 estimates are unchanged with revenue of $180-$200 million and Diluted EPS of $0.40-$0.50 per share.

Tailwinds

  • Third quarter 2023 revenue is estimated to be $49-$51 million, an increase of approximately 20% from Q3 2022.
  • Full year 2023 revenue is projected to be in the range of $180-$200 million.
  • The company is making significant progress as a leader in at-home pain management devices.
  • Zynex has a robust and durable business model with high recurring revenue.
  • The hospital monitoring division represents a large and growing market opportunity.

Headwinds

  • Diluted EPS for Q3 2023 is estimated to be $0.08-$0.10.
  • Diluted EPS is impacted by increased operating expenses to support ZMS.
  • The Laser-based Pulse Oximetry products are being prepared for FDA submission, incurring costs.
  • The fluid monitor is being readied for the market, contributing to increased expenses.
  • Labor market conditions and sales rep productivity may affect the revenue range.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.4%

Avg return

Earnings day

-1.8%

Avg return

5 days after

-6.5%

Avg return

30 days after

46%

29 / 63 earnings

Positive

+38.5%

Q3 2014

Best reaction

-51.6%

Q1 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-51.3%
Q3 2025+0.0%+0.0%-98.2%
Q2 2025+0.0%+0.0%+0.0%
Q1 2025-25.6%+0.0%+0.0%
Q3 2024+9.1%+0.0%+0.0%
Q2 2024-11.4%+0.0%+0.0%
Q1 2024+2.8%+0.0%+0.0%
Q4 2023-8.8%+0.0%+0.0%
Q3 2023+17.5%+0.0%+0.0%
Q2 2023+3.3%+0.0%+0.0%
Q1 2023+2.5%+0.0%+0.0%
Q4 2022+16.7%+0.0%+0.0%
Q3 2022+15.0%+0.0%+0.0%
Q2 2022+13.3%+0.0%+0.0%
Q1 2022-8.6%+0.0%+0.0%
Q4 2021-1.7%+0.0%+0.0%
Q3 2021+10.0%+0.0%+0.0%
Q2 2021-19.3%+0.0%+0.0%
Q1 2021-9.2%-12.0%-6.3%
Q4 2020-21.2%-22.4%-18.8%
Q3 2020-6.5%
Q2 2020-6.0%
Q1 2020-1.1%
Q4 2019+3.1%
Q3 2019-7.9%
Q2 2019+9.8%
Q1 2019+7.9%
Q4 2018-11.1%
Q3 2018+3.4%
Q2 2018-3.3%
Q1 2018+4.5%
Q4 2017-20.7%
Q3 2017+6.6%
Q2 2017+34.6%
Q1 2017-5.6%
Q4 2016+9.7%
Q3 2016+23.1%
Q2 2016+34.8%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015-4.3%
Q2 2015-5.4%
Q4 2014+0.0%
Q1 2015+0.0%
Q3 2014+38.5%
Q2 2014+2.2%
Q1 2014-0.2%
Q4 2013-3.6%
Q3 2013+13.6%
Q2 2013+7.1%
Q1 2013+0.0%
Q4 2012+3.4%
Q3 2012+5.6%
Q2 2012-5.1%
Q1 2012-6.3%
Q4 2011+0.0%
Q3 2010+12.9%
Q3 2011+12.9%
Q2 2011+1.1%
Q1 2011-8.2%
Q4 2010+0.0%
Q2 2010+2.0%
Q1 2010-51.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro